Jefferson University Hospitals

Information For

Provider Profile

Pierluigi Porcu, MD

Jefferson University Physician

Academic Title: Professor
Director, Division of Medical Oncology and Hematopoietic Stem Cell Transplantation

Specialties
Medical Oncology
Medical Oncology - Hematologic Malignancies
Medical Oncology - Leukemia/Lymphoma

Make An Appointment

Click to call 1-800-JEFF-NOW (800-533-3669) or

Request an Appointment Online

Office Locations

Philadelphia

925 Chestnut Street
Suite 420A
Philadelphia PA 19107
Phone: (215) 955-8874
Fax: (215) 955-9641

Overview
Insurances Accepted
Diagnoses & Treatments
Publications

Medical Services

Medical Oncology

Board Certifications

Medical Oncology

Hospital Affiliation / Admitting Privileges

Thomas Jefferson University Hospital

Awards and Honors

Philadelphia Magazine's Top Docs 2018

Personal Statement

I am a Physician Scientist focused on T/NK-cell lymphomas and EBV-associated lymphomas. My goal is to offer patients a roadmap to understand their illness, find the determination to fight, select the best treatment and move forward with confidence. My overarching principle is patient empowerment based on knowledge. The more people know, the more prepared they are to face adversities. Knowledge guides expectations and grounds hope in facts. Great cancer care is based on compassion and research.

Education

Univ di Torino, Italy, Medical School

Internship

Indiana University Medical Center

Insurances Accepted

Jefferson physicians accept most health insurance plans, including those listed below. However, plan acceptance may vary by practice and may be subject to change. If you have questions about whether a specific physician accepts your insurance, please contact your insurance company.

Insurances Accepted

Diagnoses & Treatments

Conditions

Cutaneous T Cell Lymphoma

Recent Publications

Duvelisib, a novel oral dual inhibitor of PI3K-d,g, is clinically active in advanced hematologic malignancies

Activity of the PI3K-δ,g inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma

Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma

Editorial: Murine models of leukemia and lymphoma

A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas

Higher rates of relapse in maternal recipients of haploidentical hematopoietic stem cell transplantation from adult offspring donors for AML and myelodysplastic syndrome

Expanding and expounding the genomic map of CTCL

A positive randomised trial in cutaneous T-cell lymphoma

Frequency and clinical correlates of elevated plasma Epstein-Barr virus DNA at diagnosis in peripheral T-cell lymphomas

Emerging insights on the pathogenesis and treatment of extranodal NK/T cell lymphomas (ENKTL)

NCCN guidelines® insights chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017: Featured updates to the NCCN guidelines

Overview of the use of murine models in leukemia and lymphoma research

Systemic therapy for cutaneous T-cell lymphoma: who, when, what, and why?

MicroRNA-181 contributes to downregulation of SAMHD1 expression in CD4+ T-cells derived from Sèzary syndrome patients

Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: A multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium

Sézary Syndrome: Clinical and Biological Aspects

Cutaneous mantle cell lymphoma: a clinicopathologic review of 10 cases

Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases

Mechanism, consequences, and therapeutic targeting of abnormal IL15 signaling in cutaneous T-cell lymphoma

NCCN Guidelines® insights: Non-Hodgkin's lymphomas, version 3.2016 featured updates to the NCCN guidelines